News

Video

Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years

Author(s):

Hussein A. Tawbi, MD, PhD

A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.

Related Videos
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Thach-Giao Truong, MD, medical director, Melanoma Program, Cleveland Clinic
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Alexander C. Van Akkooi, MD, PhD, FRACS
Meredith McKean, MD
Related Content
Martin Wermke, MD
October 10th 2024

IMA203 Displays Efficacy in Heavily Pretreated Melanoma

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Meredith McKean, MD, of Sarah Cannon Research Institute
September 16th 2024

Fianlimab/Cemiplimab Demonstrates Persistent Activity in Advanced Melanoma, Independent of LAG-3 and PD-L1 Status

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Caroline Robert, MD, PhD
September 15th 2024

RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma

Caroline Robert, MD, PhD
September 15th 2024

Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma